04 Nov 2013 Posted in ABPI statement By Press Office
Stephen added: "We are delighted that the draft Concordat on the openness on the use of animals in research in the UK is now going out for public consultation. This represents a historic change in how the life sciences sector communicates with the public.
“Research using animals plays a small but essential role in medical, veterinary and scientific progress, and is helping us to better understand and improve the treatment of diseases in humans and animals. It is vitally important that the public have accurate and up-to-date information about what animal research involves, the role it plays in the overall process of scientific discovery and treatment development, and what researchers and animal care staff do to try to reduce animal usage and minimise harm to the animals. We await with interest the results of the consultation and look forward to reviewing them.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.